Ivonescimab Combined With Chemotherapy Improves Progression Free Survival in EGFR Mutated NSCLC
Trial shows ivonescimab plus chemotherapy improves lung cancer outcomes
Ivonescimab plus pemetrexed and carboplatin significantly extends progression-free survival for patients with advanced EGFR-mutated NSCLC.
A new treatment combination involving ivonescimab and chemotherapy showed a significant improvement in progression-free survival for certain…
Immunotherapy regimens for TKI-resistant NSCLC are not cost-effective without significant price reductions
New lung cancer treatments show better results but higher costs
This network meta-analysis evaluated the cost-effectiveness of three immunotherapy-based combinations compared to chemotherapy in patients w…
Newer drug combinations offer better survival for certain lung cancer patients, but high costs currently make them difficult to fund widely.
Ivonescimab-containing chemoimmunotherapy can trigger rare ADAMTS13 inhibitor-positive immune thrombotic thrombocytopenic purpura
New Case Highlights Rare Kidney Risk in Lung Cancer Treatment
This case report and literature review describes a patient with stage IVB lung adenocarcinoma who developed iTTP after receiving an ivonesci…
A single case report identifies a rare blood and kidney condition that can occur during specific lung cancer treatments involving ivonescima…
Ivonescimab plus chemotherapy improves overall survival in patients with EGFR-variant nonsquamous NSCLC
Trial shows ivonescimab extends life for certain lung cancer patients
Researchers evaluated the addition of ivonescimab to pemetrexed and carboplatin chemotherapy for patients with advanced NSCLC who previously…
A new drug combination showed a significant improvement in survival rates for patients with specific types of advanced lung cancer.
Chemo combinations with ivonescimab, sacituzumab tirumotecan, and amivantamab show significant progression-free survival benefits
New Treatment Combinations Show Promise for Advanced Lung Cancer
This systematic review and meta-analysis of 3,606 patients evaluated 8 treatment strategies for advanced EGFR-mutant NSCLC. The analysis fou…
Specific drug combinations, including ivonescimab and amivantamab, show potential benefits for patients with advanced EGFR-mutant lung cance…
Case report on ivonescimab for EGFR-TKI-resistant lung adenocarcinoma with pericardial effusion
One Drug Shrinks Lung Tumors When Others Stop Working
This is a case report and literature review of a 77-year-old female with EGFR-TKI-resistant advanced lung adenocarcinoma and malignant peric…
A 77-year-old woman with advanced lung cancer saw her tumors shrink and dangerous fluid around her heart disappear after trying a new drug c…
Ivonescimab Phase II Study Targets 55% DCR in Relapsed Pleural Mesothelioma
Could This New Drug Offer Hope for Patients with Returning Pleural Mesothelioma?
A Phase II trial evaluates ivonescimab in 38 pleural mesothelioma patients post-immunotherapy/chemotherapy. The study aims for a ≥55% diseas…
Patients with returning pleural mesothelioma may find hope in ivonescimab, a new drug being tested to control stubborn cancer after standard…